Atrial fibrillation and heart failure are significant challenges in cardiovascular medicine, often coexisting and exacerbating each other’s impact on patient health, leading to increased morbidity and mortality rates. Managing patients with both AF and HF is complicated because many medications effective for AF are not suitable when HF is present, especially in cases of HF with reduced ejection fraction. However, recent research supports the use of catheter ablation in patients with both conditions. AF is the prevailing sustained cardiac arrhythmia in adults and is becoming more prevalent due to improved survival rates in cardiovascular disease and an aging population. It occurs in approximately 25% of HF cases. Despite extensive research, the most effective long-term strategies for managing HF and AF together remain unclear. Treatment for AF in HF patients is intricate and may improve over time with advancements in catheter-based techniques or HF medications. Current literature emphasizes the negative impact of AF on left-ventricular function and the advantages of a rhythm-controlled approach. Clinical trials in patients with AF and HF demonstrate that rhythm control through catheter ablation, specifically pulmonary vein isolation, can enhance symptoms, quality of life, and left-ventricular ejection fraction (LVEF). Increasing evidence indicates improvements in critical outcomes such as mortality and HF hospitalization with rhythm control, especially when applied early and through pulmonary vein isolation. However, catheter ablation should be used selectively, considering the patient’s comorbidities and risk factors. If sinus rhytm cannot be restored and AF becomes permanent, discussing the option of AV-node ablation and CRT implantation with the patient in a timely manner is essential. Future research efforts should focus on high-power short-duration ablation, pulsed field ablation, and hybrid/convergent AF ablation strategies for individuals with AF and HF.